Physiological and behavioural responsivity to stress and anxiogenic stimuli in COMT-deficient mice

Behavioural Brain Research

Volumn 228, Issue 2, 2012, Pages 351-358

  Desbonnet, Lieve ^a   Tighe, Orna ^a   Karayiorgou, Maria ^b   Gogos, Joseph A ^b,c   Waddington, John L ^a   O'Tuathaigh, Colm M P ^a,c  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Anxiety; Catechol O methyltransferase; Corticosterone; Cytokine expression; Mutant phenotype; Stress responsivity

Indexed keywords

CATECHOL METHYLTRANSFERASE; CHLORDIAZEPOXIDE; CORTICOSTERONE; MIDAZOLAM; TOLCAPONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME DEFICIENCY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; MOUSE; NONHUMAN; OPEN FIELD TEST; PHENOTYPE; PRIORITY JOURNAL; STRESS; TREATMENT RESPONSE;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-ANXIETY AGENTS; BEHAVIOR, ANIMAL; BENZOPHENONES; CATECHOL O-METHYLTRANSFERASE; CHLORDIAZEPOXIDE; CORTICOSTERONE; CYTOKINES; DARK ADAPTATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDAZOLAM; NITROPHENOLS; ORGAN SIZE; RESTRAINT, PHYSICAL; STATISTICS AS TOPIC; STRESS, PSYCHOLOGICAL; TIME FACTORS;

EID: 84856212152     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.12.014     Document Type: Article

References (78)

1. Gogos J.A., Morgan M., Luine V., Santha M., Ogawa S., Pfaff D., et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci USA 1998, 95:9991-9996.
2. Tunbridge E.M., Bannerman D.M., Sharp T., Harrison P.J. Catechol-O-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex. J Neurosci 2004, 24:5331-5335.
3. Tunbridge E.M. The catechol-O-methyltransferase gene: its regulation and polymorphisms. Int Rev Neurobiol 2010, 95:7-27.
4. Tunbridge E.M., Harrison P.J., Weinberger D.R. Catechol-O-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry 2006, 60:141-151.
5. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., et al. Effect of COMT Val108/158Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 2001, 98:6917-6922.
6. Allen N.C., Bagade S., McQueen M.B., Ioannidis J.P.A., Kavvoura F.K., Khoury M.J., et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet 2008, 40:827-834.
7. Okochi T., Ikeda M., Kishi T., Kawashima K., Kinoshita Y., Kitajima T., et al. Meta-analysis of association between genetic variants in COMT and schizophrenia: an update. Schizophr Res 2009, 110:140-148.
8. Domschke K., Freitag C.M., Kuhlenbaumer G., Schirmacher A., Sand P., Nyhuis P., et al. Association of the functional V158M catechol-O-methyl-transferase polymorphism with panic disorder in women. Int J Neuropsychopharmacol 2004, 7:183-188.
9. Rothe C., Koszycki D., Bradwejn J., King N., Deluca V., Tharmalingam S., et al. Association of the Val158Met catechol-O-methyltransferase genetic polymorphism with panic disorder. Neuropsychopharmacology 2006, 31:2237-2242.
10. Ursini G., Bollati V., Fazio L., Porcelli A., Lacovelli L., Catalani A., et al. Stress-related methylation of the catechol-O-methyltransferase Val 158 allele predicts human prefrontal cognition and activity. J Neurosci 2011, 31:6692-6698.
11. Jabbi M., Korf J., Kema I.P., Hartman C., van der Pompe G., Minderaa R.B., et al. Convergent genetic modulation of the endocrine stress response involves polymorphic variations of 5-HTT, COMT and MAOA. Mol Psychiatry 2007, 12:483-490.
12. Jabbi M., Kema I.P., van der Pompe G., te Meerman G.J., Ormel J., den Boer J.A. Catechol-O-methyltransferase polymorphism and susceptibility to major depressive disorder modulates psychological stress response. Psychiatr Genet 2007, 17:183-193.
13. Walder D.J., Trotman H.D., Cubells J.F., Brasfield J., Tang Y.L., Walker E.F. Catechol-O-methyltransferase modulation of cortisol secretion in psychiatrically at-risk and healthy adolescents. Psychiatr Genet 2010, 20:166-170.
14. Smolka M.N., Schumann G., Wrase J., Grusser S.M., Flor H., Mann K., et al. Catechol-O-methyltransferase val158met genotype affects processing of emotional stimuli in the amygdale and prefrontal cortex. J Neurosci 2005, 25:836-842.
15. Domschke K., Deckert J., O'donovan M.C., Glatt S.J. Meta-analysis of COMT val158met in panic disorder: ethnic heterogeneity and gender specificity. Am J Med Genet B Neuropsychiatr Genet 2007, 144B:667-673.
16. Hettema J.M., An S.S., Bukszar J., van den Oord E.J., Neale M.C., Kendler K.S., et al. Catechol-O-methyltransferase contributes to genetic susceptibility shared among anxiety spectrum phenotypes. Biol Psychiatry 2008, 64:302-310.
17. Collip D., Van Winkel R., Peerbooms O., Lataster T., Thewissen V., Lardinois M., et al. COMT Val158Met-stress interaction in psychosis: role of background psychosis risk. CNS Neurosci Ther 2011, 17:612-619.
18. Papaleo F., Crawley J.N., Song J., Lipska B.K., Pickel J., Weinberger D.R., et al. Genetic dissection of the role of catechol-O-methyltransferase in cognition and stress reactivity in mice. J Neurosci 2008, 28:8709-8723.
19. Suzuki G., Harper K.M., Hiramoto T., Funke B., Lee M., Kang G., et al. Over-expression of a human chromosome 22q11.2 segment including TXNRD2, COMT and ARVCF developmentally affects incentive learning and working memory in mice. Hum Mol Genet 2009, 18:3914-3925.
20. Haasio K., Huotari M., Nissinen E. Tissue histopathology, clinical chemistry and behaviour of adult Comt-gene-disrupted mice. J Appl Toxicol 2003, 23:213-219.
21. Harrison P.J., Tunbridge E.M. Catechol-O-methyltransferase (COMT): a gene contributing to sex differences in brain function, and to sexual dimorphism in the predisposition to psychiatric disorders. Neuropsychopharmacology 2008, 33:3037-3045.
22. Babovic D., O'Tuathaigh C.M., O'Connor A.M., O'Sullivan G.J., Tighe O., Croke D.T., et al. Phenotypic characterization of cognition and social behavior in mice with heterozygous versus homozygous deletion of catechol-O-methyltransferase. Neuroscience 2008, 155:1021-1029.
23. Spangler E., Cote D.M., Anacker A.M., Mark G.P., Ryabinin A.E. Differential sensitivity of the perioculomotor urocortin-containing neurons to ethanol, psychostimulants and stress in mice and rats. Neuroscience 2009, 160:115-125.
24. Yun J., Koike H., Ibi D., Toth E., Mizoguchi H., Nitta A., et al. Chronic restraint stress impairs neurogenesis and hippocampus-dependent fear memory in mice: possible involvement of a brain-specific transcription factor Npas4. J Neurochem 2010, 114:1840-1851.
25. Rosenbrock H., Koros E., Bloching A., Podhorna J., Borsini F. Effect of chronic intermittent restraint stress on hippocampal expression of marker proteins for synaptic plasticity and progenitor cell proliferation in rats. Brain Res 2005, 1040:55-63.
26. Xu H., Chen Z., He J., Haimanot S., Li X., Dyck L., et al. Synergistic effects of quetiapine and venlafaxine in preventing the chronic restraint stress-induced decrease in cell proliferation and BDNF expression in rat hippocampus. Hippocampus 2006, 16:551-559.
27. Paterlini M., Zakharenko S.S., Lai W.S., Qin J., Zhang H., Mukai J., et al. Transcriptional and behavioral interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice. Nat Neurosci 2005, 8:1586-1594.
28. Lapish C.C., Ahn S., Evangelista L.M., So K., Seamans J.K., Phillips A.G. Tolcapone enhances food-evoked dopamine efflux and executive memory processes mediated by the rat prefrontal cortex. Psychopharmacology 2009, 202:521-530.
29. Bourin M., Hascoet M. The mouse light/dark box test. Eur J Pharmacol 2003, 463:55-65.
30. Serova L.I., Harris H.A., Maharjan S., Sabban E.L. Modulation of responses to stress by estradiol benzoate and selective estrogen receptor agonists. J Endocrinol 2010, 205:253-262.
31. Pruett S.B., Fan R., Zheng Q., Schwab C. Patterns of immunotoxicity associated with chronic as compared with acute exposure to chemical or physical stressors and their relevance with regard to the role of stress and with regard to immunotoxicity testing. Toxicol Sci 2009, 109:265-275.
32. Frick L.R., Rapanelli M., Bussmann U.A., Klecha A.J., Arcos M.L., Genaro A.M., et al. Involvement of thyroid hormones in the alterations of T-cell immunity and tumor progression induced by chronic stress. Biol Psychiatry 2009, 65:935-942.
33. Bowers S.L., Bilbo S.D., Dhabhar F.S., Nelson R.J. Stressor-specific alterations in corticosterone and immune responses in mice. Brain Behav Immun 2008, 22:105-113.
34. Alexander N., Osinsky R., Kueller E., Schmitz A., Guenthert S., Kuepper Y., et al. Genetic variants within the dopaminergic system interact to modulate endocrine stress reactivity and recovery. Behav Brain Res 2011, 216:53-58.
35. Bilkei-Gorzo A., Racz I., Michel K., Mauer D., Zimmer A., Klingmüller D., et al. Control of hormonal stress reactivity by the endogenous opioid system. Psychoneuroendocrinology 2008, 33:425-436.
36. Groenink L., Compaan J., van der Gugten J., Zethof T., van der Heyden J., Olivier B. Stress-induced hyperthermia in mice: pharmacological and endocrinological aspects. Ann N Y Acad Sci 1995, 771:252-256.
37. Costa-Pinto F.A., Palermo-Neto J. Neuroimmune interactions in stress. Neuroimmunomodulation 2010, 17:196-199.
38. Rivest S. Interactions between the immune and neuroendocrine systems. Prog Brain Res 2010, 181:43-53.
39. Leonard B.E. The HPA and immune axes in stress: the involvement of the serotonergic system. Eur Psychiatry 2005, 20:S302-S306.
40. Leonard B.E., Myint A. The psychoneuroimmunology of depression. Hum Psychopharmacol 2009, 24:165-175.
41. Schiepers O.J.G., Wichers M.C., Maes M. Cytokines and major depression. Prog Neuro-Psychopharmacol Biol Psychiatry 2005, 29:201-217.
42. Janssen D.G., Caniato R.N., Verster J.C., Baune B.T. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol 2010, 25:201-215.
43. Dean B. Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. Int J Neuropsychopharmacol 2010, 15:1-16.
44. Watanabe Y., Someya T., Nawa H. Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry Clin Neurosci 2010, 64:217-230.
45. Goujon E., Layé S., Parnet P., Dantzer R. Regulation of cytokine gene expression in the central nervous system by glucocorticoids: mechanisms and functional consequences. Psychoneuroendocrinology 1997, 22:S75-S80.
46. Sorrells S.F., Caso J.R., Munhoz C.D., Sapolsky R.M. The stressed CNS: when glucocorticoids aggravate inflammation. Neuron 2009, 64:33-39.
47. Li M., Wang Y., Guo R., Bai Y., Yu Z. Glucocorticoids impair microglia ability to induce T cell proliferation and Th1 polarization. Immunol Lett 2007, 109:129-137.
48. Curtin N.M., Boyle N.T., Mills K.H., Connor T.J. Psychological stress suppresses innate IFN-gamma production via glucocorticoid receptor activation: reversal by the anxiolytic chlordiazepoxide. Brain Behav Immun 2009, 23:535-547.
49. Kour K., Pandey A., Suri K.A., Satti N.K., Gupta K.K., Bani S. Restoration of stress-induced altered T cell function and corresponding cytokines patterns by Withanolide A. Int Immunopharmacol 2009, 9:1137-1144.
50. Shahzad M.M., Arevalo J.M., Armaiz-Pena G.N., Lu C., Stone R.L., Moreno-Smith M., et al. Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem 2010, 285:35462-35470.
51. Mattay V.S., Goldberg T.E., Fera F., Hariri A.R., Tessitore A., Egan M.F., et al. Catechol-O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA 2003, 100:6186-6191.
52. Van Winkel R., Isusi P., Galdos P., Echevarria E., Bilbao J.R., Martin-pagola A., et al. Evidence that the COMTVal158Met polymorphism moderates subclinical psychaotic and affective symptoms in unaffected first-degree relatives of patients with schizophrenia. Eur Psychiatry 2008, 23:219-222.
53. O'Tuathaigh C.M., Hryniewiecka M., Behan A., Tighe O., Coughlan C., Desbonnet L., et al. Chronic adolescent exposure to delta-9-tetrahydrocannabinol in COMT knockout mice: impact on phenotypes relevant to psychosis. Neuropsychopharmacology 2010, 35:2262-2273.
54. Segall S.K., Nackley A.G., Diatchenko L., Lariviere W.R., Lu X., Marron J.S., et al. Comt1 genotype and expression predicts anxiety and nociceptive sensitivity in inbred strains of mice. Genes Brain Behav 2010, 9:933-946.
55. Kember R.L., Fernandes C., Tunbridge E.M., Liu L., Paya-Cano J.L., Parsons M.J., et al. A B2 SINE insertion in the Comt1 gene (Comt1(B2i)) results in an overexpressing, behavior modifying allele present in classical inbred mouse strains. Genes Brain Behav 2010, 9:925-932.
56. Cryan J.F., Holmes A. The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 2005, 4:775-790.
57. Jacobson L.H., Cryan J.F. Genetic approaches to modelling anxiety in animals. Curr Top Behav Neurosci 2010, 2:161-201.
58. Nunes-de-Souza R.L., Canto-de-Souza A., da-Costa M., Fornari R.V., Graeff F.G., Pela I.R. Anxiety-induced antinociception in mice: effects of systemic and intra-amygdala administration of 8-OH-DPAT and midazolam. Psychopharmacology 2000, 150:300-310.
59. Savic M.M., Obradovic D.I., Ugresic N.D., Cook J.M., Yin W., Bokonjic D.R. Bidirectional effects of benzodiazepine binding site ligands in the elevated plus-maze: differential antagonism by flumazenil and beta-CCt. Pharmacol Biochem Behav 2004, 79:279-290.
60. Naidu P.S., Varvel S.A., Ahn K., Vravatt B.F., Martin B.R., Lichtman A.H. Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology 2007, 192:61-70.
61. Ramos A., Pereira E., Martins G.C., Wehrmeister T.D., Izidio G.S. Integrating the open field, elevated plus maze and light/dark box to assess different types of emotional behaviours in one single trial. Behav Brain Res 2008, 193:277-288.
62. Crawley J.N. Exploratory behaviour models of anxiety in mice. Neurosci Biobehav Rev 1985, 9:37-44.
63. Belzung C., Misslin R., Vogel E., Dodd R.H., Chapouthier G. Anxiogenic effects of methyl-beta-carboline-3-carboxylate in a light/dark choice situation. Pharmacol Biochem Behav 1987, 28:29-33.
64. Finlay J.M., Zigmond M.J., Abercrombie E.D. Increased dopamine and norepinephrine release in medial prefrontal cortex induced by acute and chronic stress: effects of diazepam. Neuroscience 1995, 64:619-628.
65. Hegarty A.A., Vogel W.H. The effect of acute and chronic diazepam treatment on stress-induced changes in cortical dopamine in the rat. Pharmacol Biochem Behav 1995, 52:771-778.
66. Dazzi L., Motzo C., Imperato A., Serra M., Gessa G.L., Biggio G. Modulation of basal and stress-induced release of acetylcholine and dopamine in rat brain by abecarnil and imidazenil, two anxioselective gamma-aminobutyric acid A receptor modulators. J Pharmacol Exp Ther 1995, 273:241-247.
67. Feenstra M.G., Botterblom M.H., van Uum J.F. Novelty-induced increase in dopamine release in the rat prefrontal cortex: inhibition by diazepam. Neurosci Lett 1995, 189:81-84.
68. Vilkman H., Kajander J., Aalto S., Vahlberg T., Nagren K., Allonen T., et al. The effects of lorazepam on extrastriatal dopamine D(2/3)-receptors-A double-blind randomized placebo-controlled PET study. Psychiatry Res 2009, 174:130-137.
69. Karayiorgou M., Altemus M., Galke B.L., Goldman D., Murphy D., Ott J., et al. Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive compulsive disorder. Proc Natl Acad Sci USA 1997, 94:4572-4575.
70. Karayiorgou M., Sobin C., Blundell M.L., Galke B.L., Malinova L., Goldberg P., et al. Family-based association studies support a sexually dimorphic effect of COMT and MAOA on genetic susceptibility to obsessive-compulsive disorder. Biol Psychiatry 1999, 45:1178-1189.
71. Poyurovsky M., Michaelovsky E., Frisch A., Knoll G., Amir I., Finkel B., et al. COMT Vall58Met polymorphism in schizophrenia with obsessive-compulsive disorder: a case-control study. Neurosci Lett 2005, 389:21-24.
72. Denys D., Van Nieuwerburgh F., Deforce D., Westenberg H. Association between the dopamine D2 receptor TaqI A2 allele and low activity COMT allele with obsessive-compulsive disorder in males. Eur Neuropsychopharmacol 2006, 16:446-450.
73. Pooley E.C., Fineberg N., Harrison P.J. The met158 allele of catechol-O-methyltransferase (COMT) is associated with obsessive-compulsive disorder in men: case-control study and meta-analysis. Mol Psychiatry 2007, 12:556-561.
74. Xie T., Ho S.L., Ramsden D. Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. Mol Pharmacol 1999, 56:31-38.
75. Jiang H., Xie T., Ramsden D.B., Ho S.L. Human catechol-O-methyltransferase down-regulation by estradiol. Neuropharmacology 2003, 45:1011-1018.
76. Kawakami S.E., Quadros I.M., Takahashi S., Suchecki D. Long maternal separation accelerates behavioural sensitization to ethanol in female, but not in male mice. Behav Brain Res 2007, 184:109-116.
77. Autry A.E., Adachi M., Cheng P., Monteggia L.M. Gender-specific impact of brain-derived neurotrophic factor signaling on stress-induced depression-like behavior. Biol Psychiatry 2009, 66:84-90.
78. Lodge D.J., Grace A.A. Developmental pathology, dopamine, stress and schizophrenia. Int J Dev Neurosci 2011, 29:207-213.